Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).
Cellectis is a biotech company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART).
Medigene is a biotech company focusing on the development of personalized T-cell immunotherapies. Medigene develops highly innovative treatment platforms concentrating on haematological malignancies, cancer and autoimmune diseases.
Adaptimmune is focused on T cells to target and destroy cancer by using engineered, increased affinity T cell receptors (TCRs) as a means of strengthening natural patient T cell responses.